chr14-94378528-G-A
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_000295.5(SERPINA1):c.1178C>T(p.Pro393Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000682 in 1,613,972 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P393S) has been classified as Pathogenic.
Frequency
Consequence
NM_000295.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SERPINA1 | NM_000295.5 | c.1178C>T | p.Pro393Leu | missense_variant | 5/5 | ENST00000393087.9 | NP_000286.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SERPINA1 | ENST00000393087.9 | c.1178C>T | p.Pro393Leu | missense_variant | 5/5 | 1 | NM_000295.5 | ENSP00000376802 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000105 AC: 16AN: 152088Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000477 AC: 12AN: 251476Hom.: 0 AF XY: 0.0000441 AC XY: 6AN XY: 135908
GnomAD4 exome AF: 0.0000643 AC: 94AN: 1461884Hom.: 0 Cov.: 33 AF XY: 0.0000564 AC XY: 41AN XY: 727244
GnomAD4 genome AF: 0.000105 AC: 16AN: 152088Hom.: 0 Cov.: 33 AF XY: 0.000135 AC XY: 10AN XY: 74284
ClinVar
Submissions by phenotype
Alpha-1-antitrypsin deficiency Pathogenic:7
Pathogenic, no assertion criteria provided | literature only | GeneReviews | May 01, 2014 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Department of Laboratory Medicine and Genetics, Trillium Health Partners Credit Valley Hospital | Dec 08, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 07, 2023 | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 393 of the SERPINA1 protein (p.Pro393Leu). This variant is present in population databases (rs199422209, gnomAD 0.01%). This missense change has been observed in individuals with autosomal recessive alpha-1-antitrypsin deficiency (AATD) (PMID: 2784123, 10234508, 18024524). This variant is also known as MHerleen and as Pro369Leu. ClinVar contains an entry for this variant (Variation ID: 17965). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SERPINA1 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects SERPINA1 function (PMID: 10234508). This variant disrupts the p.Pro393 amino acid residue in SERPINA1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10234508, 18024524, 27296815). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Sep 09, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Jul 03, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 08, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 19, 2024 | - - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 14, 2017 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
SERPINA1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 15, 2024 | The SERPINA1 c.1178C>T variant is predicted to result in the amino acid substitution p.Pro393Leu. This variant has been reported in multiple individuals with alpha-1-antitrypsin deficiency and has been referred to as the PI MHeerlen allele (Hofker et al. 1989. PubMed ID: 2784123; Poller et al. 1999. PubMed ID: 10234508; Giacopuzzi et al. 2018. PubMed ID: 29882371). Functional studies found this variant results in retention of the protein in the endoplasmic reticulum (Poller et al. 1999. PubMed ID: 10234508). This variant is reported in 0.011% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 14, 2017 | The p.P393L pathogenic mutation (also known as c.1178C>T), located in coding exon 4 of the SERPINA1 gene, results from a C to T substitution at nucleotide position 1178. The proline at codon 393 is replaced by leucine, an amino acid with similar properties. This mutation comprises the deficiency allele PI*Mheerlen. The resulting mutant protein is not secreted but is retained in the endoplasmic reticulum (Poller W et al. Eur. J. Hum. Genet., 1999 Apr;7:321-31). This mutation was identified in an individual in trans with a null allele with severe chronic obstructive pulmonary disease and extremely low serum alpha-1-antitrypsin levels (Poller W et al. Eur. J. Hum. Genet., 1999 Apr;7:321-31). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
PI M(HEERLEN) Other:1
other, no assertion criteria provided | literature only | OMIM | Jul 20, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at